22 results about "Cardiac failure therapy" patented technology

This document relates to devices and methods for the treatment of heart conditions. For example, this document provides devices and methods for treating heart failure with preserved ejection fraction, including diastolic heart failure, by performing a pericardial modification procedure.

The invention provides application of kestose in preparation of a medicine for treating heart failure related diseases, and belongs to the technical field of biological medicine. The prominent application value of the natural compound kestose in prevention and treatment of heart failure related diseases is disclosed for the first time. The traditional Chinese medicine composition has the direct effects of remarkably improving cardiac insufficiency and relieving myocardial injury; in the aspect of product application, a brand-new choice of a heart failure treatment medicine derived from a natural product is provided for clinic, the medicine has a good myocardial protection effect, a solid foundation is laid for developing a targeted treatment strategy aiming at a specific pathological link of chronic cross-induction, and the application has a wide application prospect. Important theoretical significance and wide clinical application prospects are realized.

The invention discloses a motion intervention heart failure repair method based on Lgmn signal regulation and control, and relates to the technical field of heart failure treatment. According to the method, through aerobic exercise training (AET) with specific parameters, expression of Legumain (Lgmn) genes in macrophages is regulated in a targeted mode, the interburial effect of the macrophages is enhanced, then cell communication between the macrophages and cardiac muscle cells is enhanced, removal of the vertical death cardiac muscle cells is promoted, myocardial fibrosis and inflammatory response are relieved, and the effect of treating myocardial fibrosis is achieved. Finally, ventricular remodeling and heart functions of chronic heart failure (CHF) mice are improved. Experimental verification shows that the exercise intervention method can significantly improve the left ventricular ejection fraction (LVEF) and shortening fraction (FS) of CHF model animals, reduce the left ventricular end-of-systole inner diameter (LVESD), reduce myocardial cell apoptosis and necrosis, and promote inflammation regression. Drug intervention is not needed, safety is high, operation is easy and convenient, and a new effective way is provided for clinical rehabilitation treatment of heart failure.

The invention relates to application of SLCO5A1 in preparation of a medicine for treating and / or preventing heart failure. The medicine is used for up-regulating expression of SLCO5A1 protein in myocardial cells; active ingredients of the medicine comprise 3-iodothyronine, the application of the SLCO5A1 target in treating heart failure is provided for the first time, differential expression of the SLCO5A1 in a plurality of heart failure animal models and the 3-iodothyronine serving as a pharmacological effector molecule of the SLCO5A1 are disclosed, and a treatment strategy with a brand-new action mechanism is provided for heart failure treatment.

This invention belongs to the field of pharmaceutical technology, specifically relating to the application of an MHC lactation modifier in the preparation of drugs for diseases related to promoting the body's lactation level. Specifically, it relates to the application of an MHC lactation modifier in the preparation of drugs for diseases related to promoting the body's lactation level, and the application of an MHC lactation modifier in the preparation of drugs for heart failure. The heart failure is defined as heart failure caused by decreased α-MHC-K1897 lactation due to Ang II-induced vasoconstriction. The invention also relates to the application of the aforementioned MHC lactation modifier in the preparation of drugs for heart failure caused by Ang II-induced vasoconstriction in humans, mice, or dogs. This invention also discovers new uses for p300 activators and SIRT1 inhibitors. Experimental studies have shown that treatment with p300 activators and SIRT1 inhibitors can affect the level of Myh6-K1897 lactation in the treatment of heart failure. The modification of Myh6-K1897 lactation as a therapeutic target plays an important role in the treatment of heart failure, providing a new approach to the treatment of heart failure.

The invention discloses application of TRPML1 or an agonist thereof in preparation of a medicine for inhibiting myocardial cell hypertrophy and heart failure. According to the application disclosed by the invention, it is found through an in-vitro cell experiment and an in-vivo animal experiment that the TRPML1 (TRPML1) has a remarkable effect of resisting myocardial cell hypertrophy and heart failure. In addition, a mechanism of TRPML1 resisting heart failure is explored by adopting a proteomics technology and a molecular docking means, and the application basic theory is firm. On the basis, the invention provides a new strategy for treating myocardial cell hypertrophy and heart failure based on TRPML1 for the first time, the application of TRPML1 in clinical treatment of heart failure is promoted, the time from drug discovery to clinical transformation is greatly shortened, and the application has important clinical significance in treatment of myocardial cell hypertrophy and heart failure.

A heart failure management system for a patient includes a plurality of sensors including at least one implantable pressure sensor positioned within the heart to capture synchronized left and right heart pressure waveforms, transmitted via one or more transmitters to a receiver. Control circuitry receives these waveforms and processes them using a machine learning medication dosage management model, trained on historical left and right heart pressure logs, volume status metrics (e.g., weight, fluid intake, symptoms), and / or ground truth dosage logs for certain heart failure treatment medications, such as a blood pressure reducing medication (e.g., ARNI) and an intravascular volume reducing medication (e.g., Lasix). The model can generate real-time dosage recommendations, systemic blood pressure, and volume load predictions in real-time, enabling precise, data-driven treatment adjustments aligned with clinical guidelines, supporting timely clinical decisions or automated medication dispensing to optimize patient outcomes and reduce hospitalization risks.

The application relates to application of miRNA and / or a miRNA agonist in preparation of a medicine for preventing and / or treating myocardial ischemia-reperfusion injury, and belongs to the technical field of biological medicine. The medicine is administered through skeletal muscle injection, is secreted to a circulation system after expression on the skeletal muscle, is delivered to heart tissue by taking extracellular vesicles as carriers, and thus regulates myocardial cell functions. According to the animal model verification result, the miRNA can be delivered to the heart by the extracellular vesicles secreted by the skeletal muscle through injection of the medicine into the skeletal muscle, the expression level of the miRNA in the I / RI heart is significantly increased, the myocardial infarction area is effectively reduced, myocardial cell apoptosis is inhibited, myocardial fibrosis is reduced, and heart function is improved, a brand-new intervention strategy is provided for treatment of myocardial ischemia-reperfusion injury and related heart diseases, and a brand-new idea is opened up for research and development of heart failure treatment medicines.

The application discloses an application of an SIAH2 inhibitor to treating heart failure or improving myocardial cell function, relates to the technical field of medicine, and is used for researching the treatment effect and mechanism of SIAH2 on heart failure. The application provides an application of an SIAH2 gene or protein inhibitor to preparing a heart failure medicine, uses the SIAH2 inhibitor to intervene in a TAC-induced mouse heart failure model, finds that the SIAH2 inhibitor can improve myocardial energy metabolism and protect heart function, and provides a new target and strategy for clinically diagnosing and treating heart failure or improving myocardial cell function.

The present disclosure relates methods of treating heart failure, such as heart failure with preserved ejection fraction, wherein said methods reduce cardiac inflammation and / or improve cardiac function by targeting pro-inflammatory cells and cytokines in a subject, including but not limited to subjects in the aging population.

An aspect of some embodiments of the invention relates to providing acute non-excitatory electrical heart failure therapy to a patient according to one or more criteria. Exemplary criteria are one or more of suffering from an acute angina episode, a patient after a myocardial infraction episode, a patient after heart surgery, a patient that is already on a Cath-Lab and would be beneficial to see if the treatment could help the patient, patients that suffer from heart failure and optionally already receive chronic non-excitatory electrical heart failure therapy, a patient that requires an improvement in blood flow, patients that show positive results from trial activation of acute non-excitatory electrical heart failure therapy, patients that require assistance in performing daily activities, like exercise, social events, after taking certain drugs, performing intercourse, sleeping and suffer from emotional stress.

Provided is a class of circular RNAs, comprising mecciND2 and mecciNd2 having nucleotide sequences set forth in SEQ ID No. 1 and SEQ ID No. 2, respectively. The mecciND2 or the mecciNd2 is capable of inhibiting excessive opening of mitochondrial permeability transition pores, thereby significantly reducing ROS levels in myocardial cells, maintaining mitochondrial activity, and further protecting the myocardial cells. Intravenously injecting mecciNd2 into a mouse model of heart failure can effectively protect cardiac function and delay the progression of heart failure. The circular RNA is used as a drug for treating heart failure and exhibits good safety and specificity.

The invention provides an application of a Cthrc1 gene in preparation of a medicine for treating cardiac hypertrophy. The Cthrc1 expression of a cardiac hypertrophy model mouse is remarkably up-regulated, the cross sectional area and fibrosis of cardiac muscle cells of a Cthrc1 gene knockout mouse are remarkably reduced, and the cardiac contraction function is remarkably improved. Based on the discovery, the Cthrc1 gene can be used as an action target of a medicine for treating the cardiac hypertrophy and the heart failure, and a reagent for knocking out the Cthrc1 gene or inhibiting the expression of the Cthrc1 gene can be used for preparing the medicine for preventing, relieving and / or treating the cardiac hypertrophy.

The invention relates to the technical field of biological medicines, in particular to application of a cream globule epidermal growth factor 8 in preparation of a medicine for treating acute heart failure. The milk fat globule epidermal growth factor 8 or the functional fragment, the modified derivative, the expression promoter and the recombinant protein thereof are used for preparing the acute heart failure treatment medicine, myocardial cell systolic dysfunction can be relieved by inhibiting the increase of the acetylation modification level of intracellular tubulin, and then acute heart failure is treated. Particularly, the acute heart failure without basic heart disease can be quickly improved.

A medical system includes an implantable cardiac device configured to monitor one or more cardio-thoracic parameters of a patient and one or more external devices configured to receive, from the implantable cardiac device, cardio-thoracic data indicative of the one or more cardio-thoracic parameters over a period of time; determine a long term heart failure risk (HFR) score for the patient based on the cardio-thoracic data; based on a change in the long term HFR score for the patient, determine a modification to a therapy plan of a second implanted device in the patient; and cause the second implanted device to implement the modified therapy plan.

The present invention relates to non-excitatory electrical heart failure therapy as a therapy for Heart failure with preserved ejection fraction.

The invention discloses application of an SIAH2 inhibitor to treatment of heart failure or improvement of myocardial cell functions, relates to the technical field of medical treatment, and is used for researching the treatment effect and the treatment mechanism of SIAH2 on heart failure. According to the application of the SIAH2 gene or protein inhibitor in preparing the medicine for treating the heart failure, the SIAH2 inhibitor is used for intervening a TAC-induced mouse heart failure model, and it is found that the SIAH2 inhibitor can improve myocardial energy metabolism and protect the heart function; the invention provides a new target and strategy for clinically diagnosing and treating heart failure or improving myocardial cell functions.

The application provides a heart failure marker and application thereof in predicting and treating heart failure, and the heart failure marker comprises an HGFAC protein. The HGFAC protein is a marker protein of heart failure, and the protein level and protein activity thereof are increased in blood of a heart failure patient, and the HGFAC protein can be used for diagnosing heart failure, evaluating heart failure classification and / or stage, predicting heart failure recurrence risk, and predicting death risk of the heart failure patient. In addition, the HGFAC protein can be used as a target for heart failure treatment, and after the HGFAC protein is inhibited, the heart function is improved, and the progression of heart failure is inhibited. Therefore, the prediction and treatment strategy based on the HGFAC protein not only widens the diagnosis and treatment ideas of heart failure, but also provides more personalized and effective treatment options for patients, and has important clinical transformation value.

Provided is an implantable heart failure treatment device, including a housing; an anchoring member, connected to the housing and fixing the housing to a heart; a pair of stimulation electrodes coupled to the housing, configured to be in contact with a predetermined stimulation position of the heart, and configured to apply an electrical stimulation pulse for enhancing cardiac contractility to the predetermined stimulation position; a pulse generation module accommodated within the housing, electrically coupled to the stimulation electrodes, and configured to generate the electrical stimulation pulse; and a control module accommodated within the housing, electrically coupled to the stimulation electrodes and the pulse generation module, and configured to: receive a far-field sense signal indicating a global excitation event of the heart of a patient and a local sense signal indicating a local excitation event of a local position of the heart of the patient; and determine, at least based on the far-field sense signal and the local sense signal, whether the local excitation event of the local position of the heart of the patient corresponds to a specific global excitation event, and transmit the electrical stimulation pulse to the stimulation electrodes in an absolute refractory period of the local excitation event.

Disclosed herein are systems and methods for management and administration of therapeutic treatment regimens for heart failure patients. In some examples, this includes monitoring a patient's heart rate and electrocardiogram using a wearable heart rate sensor to provide input into a decision tree model to provide an effective treatment regimen. Furthermore, regular blood pressure measurements may be input into the model. The system may additionally iterate through various heart failure therapeutics based on a patient's response to prior administered therapeutics.

The invention discloses a photo-activated myocardial targeting nano capsule for heart failure, and belongs to the technical field of biological medicines and nano materials. The nanometer capsule-like body comprises an inner core which is a nanometer capsule-like body unit, is obtained by nanocrystallization of a plant capsule-like body film and retains photoreaction activity; the shell is a bionic coating layer derived from a myocardial cell membrane. The invention also provides a preparation method of the nano capsule-like body and application of the nano capsule-like body in preparation of medicines for treating pressure load related cardiomyopathy (such as heart failure, cardiac hypertrophy and fibrosis). According to the nanometer cystoid, myocardial targeted enrichment is achieved through myocardial cell membrane coating, ATP is controllably generated under specific red light irradiation, myocardial cell energy metabolism defects are repaired, the mitochondrial function is improved, and therefore myocardial hypertrophy and fibrosis are effectively inhibited on cell and animal models, and the heart function is improved. The invention provides a novel energy metabolism repairing strategy which is triggered on demand and controllable in dosage for heart failure treatment.